Skip to main content
SONOSCAPE MEDICAL CORP. logo

SONOSCAPE MEDICAL CORP. — Investor Relations & Filings

Ticker · 300633 ISIN · CNE100002P91 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,204 across all filing types
Latest filing 2026-05-28 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 300633

About SONOSCAPE MEDICAL CORP.

https://www.sonoscape.com

SonoScape Medical Corp. specializes in the research, development, and manufacturing of advanced medical diagnostic equipment. The company's primary product portfolio includes high-definition ultrasound systems, flexible endoscopy solutions, and electrocardiography devices. SonoScape focuses on delivering innovative imaging technology to healthcare providers globally, ranging from portable diagnostic tools to comprehensive trolley-based systems. Their ultrasound range covers various clinical applications such as cardiology, obstetrics, and radiology, while their endoscopy division provides high-resolution video processors and scopes for gastrointestinal and respiratory procedures. The company emphasizes continuous technological advancement and clinical efficiency to improve patient outcomes and diagnostic accuracy in diverse medical settings.

Recent filings

Filing Released Lang Actions
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is an implementation announcement for the company’s 2025 annual equity distribution (cash dividend) including share base, dividend per share, total amount, record and ex-dividend dates, tax details, and procedures for dividend payment. This clearly matches a Notice of Dividend Amount filing, not a full annual report or other filing.
2026-05-28 Chinese
关于回购股份实施完成暨股份变动的公告
Transaction in Own Shares Classification · 90% confidence The document is an official announcement by Shenzhen Kaili Biomedical Technology Co., Ltd. regarding the completion of its share repurchase program and resulting changes in its share capital. It details the number of shares repurchased, prices, legal compliance, and post-repurchase procedures. This clearly falls under Transaction in Own Shares (share buybacks) rather than a financing, management change, or full financial report.
2026-05-15 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a formal announcement of the resolutions passed at the 2025 Annual General Meeting (held May 13, 2026), including detailed vote counts for each proposal. It does not present financial statements or management discussion but rather the official voting outcomes of shareholder proposals. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-13 Chinese
北京市中伦（深圳）律师事务所关于公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 75% confidence The document is a legal opinion letter (“法律意见书”) provided by a law firm reviewing the convening procedures, attendance, voting process, and vote results of the company’s 2025 annual shareholders meeting. It is not itself an annual report or interim financial report, nor is it a proxy solicitation or dividend notice. It is not a straight declaration of voting results issued by the company, but rather a compliance/legal opinion document. Since no specific category exists for standalone legal opinions, and it does not neatly fit other categories, it falls under general regulatory/compliance filing (RNS).
2026-05-13 Chinese
关于拟续聘会计师事务所的公告
Regulatory Filings Classification · 75% confidence The document is an announcement by Shenzhen Kaili Biomedical Technology Co., Ltd. regarding the proposed reappointment of its external auditor for the 2026 financial year. It outlines details of the audit firm, engagement procedures, and board/audit committee approvals, but does not itself present an audit report, financial statements, or dividend/meeting results. It is a regulatory announcement of a corporate action (auditor appointment) rather than a full annual or interim report, proxy statement, or actual audit report. It therefore falls into the fallback category for general regulatory filings.
2026-04-16 Chinese
2025年度独立董事述职报告（徐舜芝）
Governance Information Classification · 65% confidence The document is an annual performance report by the company’s independent director (独立董事述职报告), detailing governance activities, board attendance, committee work, oversight of financial reports and audits, and communications—all focused on fulfilling board governance duties rather than financial results or corporate actions. It falls under Corporate Governance Information rather than an Annual Report, Earnings Release, or Board Change Notice. Hence, the best match is Governance Information (CGR).
2026-04-16 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.